Oncolytic viruses

Oncolytic varicella-zoster virus engineered with ORF8 deletion and armed with drug-controllable interleukin-12
Haifei Jiang, Rebecca Nace, Talia Fernandez Carrasco, Lianwen Zhang, Kah Whye Peng, Stephen J Russell

Journal for ImmunoTherapy of Cancer Mar 2024, 12 (3) e008307; DOI: 10.1136/jitc-2023-008307
Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade
Fei Ju, Yong Luo, Chaolong Lin, Xian Jia, Zilong Xu, Rui Tian, Yanhua Lin, Min Zhao, Yating Chang, Xiaoxuan Huang, Shaopeng Li, Wenfeng Ren, Yaning Qin, Mengqin Yu, Jizong Jia, Jinle Han, Wenxin Luo, Jun Zhang, Guo Fu, Xiangzhong Ye, Chenghao Huang, Ningshao Xia

Journal for ImmunoTherapy of Cancer Jun 2022, 10 (6) e004762; DOI: 10.1136/jitc-2022-004762
Combination oncolytic virus, radiation therapy, and immune checkpoint inhibitor treatment in anti-PD-1-refractory cancer
Sachin R Jhawar, Shang-Jui Wang, Aditya Thandoni, Praveen K Bommareddy, Jenna H Newman, Eileena F Giurini, Amanda L Marzo, Timothy M Kuzel, Vineet Gupta, Jochen Reiser, Preston Daniels, Devora Schiff, Darrion Mitchell, Nicole R LeBoeuf, Christopher Simmons, Sharad Goyal, Ahmed Lasfar, Jose A Guevara-Patino, Bruce G Haffty, Howard L Kaufman, Ann W Silk, Andrew Zloza

Journal for ImmunoTherapy of Cancer Jul 2023, 11 (7) e006780; DOI: 10.1136/jitc-2023-006780
Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer
Thomas A Odeny, Kathryn Lurain, Julius Strauss, Steven P Fling, Elad Sharon, Anna Wright, Javier Martinez-Picado, Teresa Moran, James L Gulley, Maria Gonzalez-Cao, Thomas S Uldrick, Robert Yarchoan, Ramya Ramaswami

Journal for ImmunoTherapy of Cancer Sep 2022, 10 (9) e005128; DOI: 10.1136/jitc-2022-005128
Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial
Jason A Chesney, Igor Puzanov, Frances A Collichio, Parminder Singh, Mohammed M Milhem, John Glaspy, Omid Hamid, Merrick Ross, Philip Friedlander, Claus Garbe, Theodore Logan, Axel Hauschild, Celeste Lebbé, Harshada Joshi, Wendy Snyder, Janice M Mehnert

Journal for ImmunoTherapy of Cancer May 2023, 11 (5) e006270; DOI: 10.1136/jitc-2022-006270
Oncolytic viruses and antibodies: are they more successful when delivered separately or when engineered as a single agent?
Peter Kok-Ting Wan, Ricardo A Fernandes, Leonard W Seymour

Journal for ImmunoTherapy of Cancer Aug 2023, 11 (8) e006518; DOI: 10.1136/jitc-2022-006518
TNF blockade enhances the efficacy of myxoma virus-based oncolytic virotherapy
Miriam Valenzuela-Cardenas, Cody Gowan, Parker Dryja, Mee Y Bartee, Eric Bartee

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004770; DOI: 10.1136/jitc-2022-004770
Remodeling the tumor microenvironment by oncolytic viruses: beyond oncolysis of tumor cells for cancer treatment
Lihong Wang, Louisa S Chard Dunmall, Zhenguo Cheng, Yaohe Wang

Journal for ImmunoTherapy of Cancer May 2022, 10 (5) e004167; DOI: 10.1136/jitc-2021-004167
Commentary on oncolytic viruses: past, present, and future
Christopher Larson, Bryan Oronsky, Tony R Reid

Journal for ImmunoTherapy of Cancer Dec 2023, 11 (12) e007905; DOI: 10.1136/jitc-2023-007905
Development of the oncolytic virus, CF33, and its derivatives for peritoneal-directed treatment of gastric cancer peritoneal metastases
Annie Yang, Zhifang Zhang, Shyambabu Chaurasiya, Anthony K Park, Audrey Jung, Jianming Lu, Sang-In Kim, Saul Priceman, Yuman Fong, Yanghee Woo

Journal for ImmunoTherapy of Cancer Apr 2023, 11 (4) e006280; DOI: 10.1136/jitc-2022-006280

Main menu

Oncolytic viruses

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Oncolytic viruses

Pages